or Try an Advanced Search...

    Technical Analysis for KYMR - Kymera Therapeutics, Inc.

    Grade Last Price % Change Price Change
    D 46.05 2.29% 1.03
    KYMR closed up 2.29 percent on Monday, October 14, 2024, on 47 percent of normal volume. The stock rose above its 50 day moving average, improving its intermediate-term outlook by crossing above that important trendline.
    Earnings due: Oct 31
    *** please verify all earnings dates ***
    3 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Up Flat Up
    Historical KYMR trend table...
    Date Alert Name Type % Chg
    Crossed Above 50 DMA Bullish 0.00%
    Oversold Stochastic Weakness 2.29%
    Gapped Down Weakness 6.50%
    Oversold Stochastic Weakness 6.50%
    Oversold Stochastic Weakness 6.25%
    Stochastic Buy Signal Bullish 6.99%
    Oversold Stochastic Weakness 6.99%
    NR7 Range Contraction 9.10%
    Down 3 Days in a Row Weakness 9.10%
    Down 4 Days in a Row Weakness 9.10%
    Older End-of-Day Signals for KYMR ...

       Recent Intraday Alerts

    Alert Time
    Up 3% about 8 hours ago
    Up 2% about 10 hours ago
    50 DMA Resistance about 10 hours ago
    60 Minute Opening Range Breakout about 11 hours ago
    Rose Above 50 DMA about 11 hours ago
    View Earlier Intraday Alerts

    Get a Trading Assistant

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Get Started for Free!
    Configure default chart indicators
    KYMR Chart by TradingView
    Basic chart:

    Profile

    Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; and STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases. The company was founded in 2015 and is headquartered in Watertown, Massachusetts.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Medicine Biopharmaceutical Clinical Medicine Immunology Solid Tumors Immune System Autoimmune Disease Autoimmunity Rheumatoid Arthritis Hematologic Malignancies Atopic Dermatitis Dermatitis Hidradenitis Suppurativa

    Is KYMR a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 1 bullish, 1 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Oct 10 Kymera's IND Application for STAT6 Degrader Gets FDA Clearance
    Oct 9 Kymera gets FDA clearance for Phase 1 testing of KT-621
    Oct 9 Kymera Therapeutics Announces FDA Clearance of Investigational New Drug Application for KT-621, a First-in-Class, Oral STAT6 Degrader
    Oct 6 Kymera's Protein Degradation Technology: A Promising Bet For Long-Term Biotech Investors
    Sep 25 Kymera Therapeutics Presents Preclinical Data for KT-621, a Potent, Selective, First-In-Class, Oral STAT6 Degrader at the EADV Congress
    Sep 6 Why Is Kymera Therapeutics (KYMR) Up 10.9% Since Last Earnings Report?
    Aug 28 Kymera Therapeutics to Participate in Upcoming September Investor Conferences
    Aug 21 Kymera Therapeutics Announces Closing of Upsized $225 Million Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
    Aug 20 Kymera (KYMR) to Raise $225 Million Through Offering of Shares
    Aug 20 Biggest stock movers today: LLY, PANW, FN, and more
    See more KYMR news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 53.27
    52 Week Low 9.6
    Average Volume 414,121
    200-Day Moving Average 38.42
    50-Day Moving Average 45.86
    20-Day Moving Average 46.67
    10-Day Moving Average 44.09
    Average True Range 2.14
    RSI (14) 51.22
    ADX 19.47
    +DI 24.27
    -DI 23.55
    Chandelier Exit (Long, 3 ATRs) 46.85
    Chandelier Exit (Short, 3 ATRs) 48.03
    Upper Bollinger Bands 52.75
    Lower Bollinger Band 40.58
    Percent B (%b) 0.45
    BandWidth 26.07
    MACD Line -0.68
    MACD Signal Line -0.40
    MACD Histogram -0.2884
    Fundamentals Value
    Market Cap 2.73 Billion
    Num Shares 59.4 Million
    EPS -2.86
    Price-to-Earnings (P/E) Ratio -16.10
    Price-to-Sales 46.41
    Price-to-Book 5.59
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 48.69
    Resistance 3 (R3) 48.55 47.52 48.25
    Resistance 2 (R2) 47.52 46.85 47.60 48.10
    Resistance 1 (R1) 46.79 46.44 47.16 46.93 47.96
    Pivot Point 45.76 45.76 45.95 45.84 45.76
    Support 1 (S1) 45.03 45.09 45.40 45.17 44.14
    Support 2 (S2) 44.00 44.68 44.08 44.00
    Support 3 (S3) 43.27 44.00 43.85
    Support 4 (S4) 43.41